These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12600955)

  • 1. Comparison of eight computer programs for receiver-operating characteristic analysis.
    Stephan C; Wesseling S; Schink T; Jung K
    Clin Chem; 2003 Mar; 49(3):433-9. PubMed ID: 12600955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receiver-operating characteristic as a tool for evaluating the diagnostic performance of prostate-specific antigen and its molecular forms--What has to be considered?
    Jung K; Stephan C; Lein M; Brux B; Sinha P; Schnorr D; Loening SA
    Prostate; 2001 Mar; 46(4):307-10. PubMed ID: 11241553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
    Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH
    Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Usefulness of free prostate specific antigen in the detection of prostate cancer].
    Azócar G; Castillo O; Van Cauwelaert R; Cumsille MA; Campero JM; Aguirre C; Wöhler C
    Rev Med Chil; 1999 Feb; 127(2):151-7. PubMed ID: 10436694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Software for illustrative presentation of basic clinical characteristics of laboratory tests--GraphROC for Windows.
    Kairisto V; Poola A
    Scand J Clin Lab Invest Suppl; 1995; 222():43-60. PubMed ID: 7569746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the 'normal range' for prostate-specific antigen? Use of a receiver operating characteristic curve to evaluate a serum marker.
    Gillatt D; Reynard JM
    Br J Urol; 1995 Mar; 75(3):341-6. PubMed ID: 7537603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination and multivariate analysis of PSA-based parameters for prostate cancer prediction.
    Djavan B; Remzi M; Zlotta AR; Seitz C; Wolfram R; Hruby S; Bursa B; Schulman CC; Marberger M
    Tech Urol; 1999 Jun; 5(2):71-6. PubMed ID: 10458658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer.
    Van Cangh PJ; De Nayer P; Sauvage P; Tombal B; Elsen M; Lorge F; Opsomer R; Wese FX
    Prostate Suppl; 1996; 7():30-4. PubMed ID: 8950361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
    Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
    Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations.
    Gohji K; Nomi M; Egawa S; Morisue K; Takenaka A; Okamoto M; Ohori M; Fujii A
    Cancer; 1997 May; 79(10):1969-76. PubMed ID: 9149025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [ROC (receiver operating characteristics) curve: principles and application in biology].
    Delacour H; Servonnet A; Perrot A; Vigezzi JF; Ramirez JM
    Ann Biol Clin (Paris); 2005; 63(2):145-54. PubMed ID: 15771972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Values for free/total prostate-specific antigen ratio as a function of age: necessity of reference validation in a Turkish population.
    Mungan AG; Erol B; Akduman B; Bozdogan G; Kiran S; Yesilli C; Mungan NA
    Clin Chem Lab Med; 2007; 45(7):912-6. PubMed ID: 17617037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer.
    Wians FH; Cheli CD; Balko JA; Bruzek DJ; Chan DW; Sokoll LJ
    Clin Chim Acta; 2002 Dec; 326(1-2):81-95. PubMed ID: 12417099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer.
    Froehner M; Hakenberg OW; Koch R; Schmidt U; Meye A; Wirth MP
    Urol Int; 2006; 76(1):27-30. PubMed ID: 16401917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.
    Miller MC; O'Dowd GJ; Partin AW; Veltri RW
    Urology; 2001 Jun; 57(6):1105-11. PubMed ID: 11377319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
    Thompson IM; Ankerst DP; Chi C; Lucia MS; Goodman PJ; Crowley JJ; Parnes HL; Coltman CA
    JAMA; 2005 Jul; 294(1):66-70. PubMed ID: 15998892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
    Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
    Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
    Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
    Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proportion of prostate-specific antigen (PSA) complexed to alpha(1)-antichymotrypsin improves the discrimination between prostate cancer and benign prostatic hyperplasia in men with a total PSA of 10 to 30 microg/L.
    Martínez M; España F; Royo M; Alapont JM; Navarro S; Estellés A; Aznar J; Vera CD; Jiménez-Cruz JF
    Clin Chem; 2002 Aug; 48(8):1251-6. PubMed ID: 12142381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.